ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions

Healthy Volunteers

Interventions

DRUG

ORKA-002

ORKA-002 is supplied as sterile solution to be administered by SC injection

OTHER

Placebo

Placebo solution to be administered at a matching volume by SC injection

Trial Locations (1)

Oruka Therapeutics Investigative Site, Christchurch